Concepedia

Sarah Kearney

SK

Statistics

Publications

3

Citations

329

H-Index

3

Active since

1998

Affiliations

AstraZeneca (United Kingdom)(Current)

Sarah Kearney is an author at AstraZeneca (United Kingdom) specializing in aurora kinase function, oncology, and drug discovery.

Publications per year

1998–2008

3

Publications

3

Discovery, Synthesis, and <i>in Vivo</i> Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase

Andrew Mortlock, Kevin M. Foote, Nicola M. Heron et al. · Journal of Medicinal Chemistry · 2007 · 274 citations · Full text

Medicine, Oncology, Pharmacology +13

Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: Selective inhibitors of Aurora B kinase with potent anti-tumor activity

Kevin M. Foote, Andrew Mortlock, Nicola M. Heron et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 34 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Effect of in vivo administration of all trans-retinoic acid on the hemopoietic cell populations of the spleen and bone marrow: profound strain differences between A/J and C57BL/6J mice.

Sandra C. Miller, Sarah Kearney · PubMed · 1998 · 21 citations

Life Sciences, Immunology, Oncology +9

1–3 of 3